Abstract:BACKGROUND:Human myelogenous leukemia characterized by either the non random t(8; 21)(q22; q22) or t(16; 21)(q24; q22) chromosome translocations differ for both their biological and clinical features. Some of these features could be consequent to differential epigenetic transcriptional deregulation at AML1 targets imposed by AML1-MTG8 and AML1-MTG16, the fusion proteins deriving from the two translocations. Preliminary findings showing that these fusion proteins lead to transcriptional downregulation of AML1 targets, marked by repressive chromatin changes, would support this hypothesis. Here we show that combining conventional global gene expression arrays with the power of bioinformatic genomic survey of AML1-consensus sequences is an effective strategy to identify AML1 targets whose transcription is epigenetically downregulated by the leukemia-associated AML1-MTG16 protein. RESULTS:We interrogated mouse gene expression microarrays with probes generated either from 32D cells infected with a retroviral vector carrying AML1-MTG16 and unable of granulocyte differentiation and proliferation in response to the granulocyte colony stimulating factor (G-CSF), or from 32D cells infected with the cognate empty vector. From the analysis of differential gene expression alone (using as criteria a p value < 0.01 and an absolute fold change > 3), we were unable to conclude which of the 37 genes downregulated by AML1-MTG16 were, or not, direct AML1 targets. However, when we applied a bioinformatic approach to search for AML1-consensus sequences in the 10 Kb around the gene transcription start sites, we closed on 17 potential direct AML1 targets. By focusing on the most significantly downregulated genes, we found that both the AML1-consensus and the transcription start site chromatin regions were significantly marked by aberrant repressive histone tail changes. Further, the promoter of one of these genes, containing a CpG island, was aberrantly methylated. CONCLUSION:This study shows that a leukemia-associated fusion protein can impose a distinct epigenetic repressive signature at specific sites in the genome. These findings strengthen the conclusion that leukemia-specific oncoproteins can induce non-random epigenetic changes.

Expression and role of DJ-1 in leukemia.

DJ-1 as a human oncogene and potential therapeutic target.

Expression and Clinical Significance of ID1 Gene in Acute Myeloid Leukemia

Prognostic Significance of Huntingtin Interacting Protein 1 Expression on Patients with Acute Myeloid Leukemia

High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia from Two Cohorts.

A Novel Role for Malate Dehydrogenase 1 in Acute Myeloid Leukemia Progression

Expression and Clinical Significance of Phospholipase D1 in De Novo Acute Myeloid Leukemia

Acute Myeloid Leukemia Cell-Intrinsic PD-1 Functions Promoting Leukemia Development by Recruiting SHP2

DJ-1 as a Therapeutic Target Against Cancer.

A Distinct Epigenetic Signature at Targets of a Leukemia Protein

The Non-Cell-autonomous Function of ID1 Promotes AML Progression Via ANGPTL7 from the Microenvironment.

DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer

DJ-1 Promotes Survival of Human Colon Cancer Cells under Hypoxia by Modulating HIF-1α Expression Through the PI3K-AKT Pathway

DJ‑1 is a New Prognostic Marker and Predicts Chemotherapy Efficacy in Colorectal Cancer.

[Expression of Transcription Factor LYL1 in Leukemia and Its Possible Role in Leukemogenesis].

JMJD3 Facilitates C/EBPβ-centered Transcriptional Program to Exert Oncorepressor Activity in AML

Dj-1 As A Potential Biomarker for the Early Diagnosis in Lung Cancer Patients

DJ-1 Suppresses Cytoplasmic TDP-43 Aggregation in Oxidative Stress-Induced Cell Injury.

DJ-1 mediates regulation of metabolism and immune response in Parkinsons disease astrocytes and Glioblastoma cells

DJ-1 promotes development of DEN-induced hepatocellular carcinoma and proliferation of liver cancer cells

Overexpression of an Isoform of AML1 in Acute Leukemia and Its Potential Role in Leukemogenesis